Novo Nordisk reports five-year Victoza cardiovascular safety data
March 7, 2016Research and Development, Sales and Marketing Novo Nordisk, Victoza
Novo Nordisk has announced the top-line results from a trial investigating the cardiovascular safety of Victoza (liraglutide [rDNA origin] injection) …
FDA approves CSL Behring’s new haemophilia B treatment
March 7, 2016Research and Development, Sales and Marketing CSL Behring, haemophilia
The US Food and Drug Administration (FDA) has approved CSL Behring’s Idelvion (Coagulation Factor IX (Recombinant)), a novel, long-acting albumin …
Novartis says its psoriasis drug bests Janssen’s in comparison study
March 7, 2016Research and Development, Sales and Marketing Cosentyx, Novartis, Stelara
Novartis has announced new data from a study comparing its drug Cosentyx to Janssen’s Stelara, which it says demonstrates Cosentyx’s …
Teva suffers EpiPen generic setback after FDA rejection
March 4, 2016Medical Communications, Research and Development FDA, Teva, analphylaxis, approval, auto injector, auto-injector, rejection
The release of Teva Pharmaceuticals generic for the anaphylaxis treatment, EpiPen (epinephrine), is now expected to be severely delayed after …
BioMarin reports positive early-stage results for trial drug to treat CLN2 disease
March 4, 2016Medical Communications
Biotechnology firm BioMarin Pharmaceutical has announced positive results from early stage trial for drug to treat neurodegenerative disease in children. …
Merck & Pfizer tie-up with Verastem to develop ovarian cancer drug
March 4, 2016Medical Communications
German drug major Merck along with Pfizer has joined forces with Verastem to develop the trial drug candidate avelumab to …
Sanofi Genzyme present positive Phase 2 results for fatal neuromuscular disease treatment
March 4, 2016Medical Communications, Research and Development Pompe disease, Sanofi, clinical trial, neuromuscular, phase 2
Sanofi Genzyme, the branch of the French-based pharma company that focuses on diseases difficult to diagnose and treat, have published …
Almost half of US physicians will prescribe more biosimilars, according to survey
March 4, 2016Medical Communications Obama, US, biosimilar, patent, prescribing
New data published by InCrowd has suggested that US physicians are very amenable to the prescription of biosimilars, with some …
Baxalta seeks European marketing rights for haemophilia drug
March 3, 2016Research and Development, Sales and Marketing Adynovi haemophilia a, Baxalta
Baxalta says it has filed for marketing authorisation for its haemophilia drug Adynovi with European regulators. The European Medicines Agency …
UCB targets regulatory filing for its osteoporosis drug in 2016
March 3, 2016Medical Communications, Research and Development, Sales and Marketing Romosozumab, UCB Pharma, osteoporosis
Belgian drug company UCB says it is looking at a regulatory filing for its trial drug romosozumab to treat osteoporosis …
Merck announces drug discovery collaboration with European Molecular Biology Laboratory
March 3, 2016Research and Development Cancer, Merck, biomarkers
Merck has announced that it has entered into a research collaboration with the European Molecular Biology Laboratory (EMBL), that will …
Amgen sues Novartis over Enbrel biosimilar
March 3, 2016Research and Development, Sales and Marketing Amgen, Novartis, Sandoz, biosimilars
Amgen has filed a suit in a US court against Novartis’ generics unit Sandoz, in a bid to protect bestselling …
Valeant company group chairman and executive vice president resigns
March 3, 2016Medical Communications, Sales and Marketing Valeant, appointed, resignation
In an already troubled week for Valeant Pharmaceuticals, the company has now announced that its group chairman and executive vice …
CHMP recommends Sanofi’s two-dose schedule HPV vaccine
March 3, 2016Research and Development HPV vaccine, MSD, Sanofi Pasteur
Sanofi Pasteur’s and MSD’s vaccine against human papillomavirus (HPV), Gardasil 9, has received a positive opinion from the European Medicine …
Novo says diabetes drug Xultophy cost-effective versus insulin intensification treatment
March 2, 2016Sales and Marketing Novo Nordisk, Xultophy, diabetes
Novo Nordisk says findings show its Tresiba and Victoza combo Xultophy (insulin degludec/liraglutide: IDegLira), is cost-effective compared to insulin intensification …
Bill Griffiths joins NDA group as general manager UK
March 2, 2016Medical Communications NDA Group
Industry veteran Bill Griffiths has joined NDA Group to head up the company’s UK consulting team and NDA’s advisory board. …
FDA approves Gilead’s Odefsey for treatment of HIV-1 infection
March 2, 2016Research and Development, Sales and Marketing Gilead Sciences, HIV, Odefsey
Gilead Sciences has announced that the US Food and Drug Administration (FDA) has approved its TAF-based single tablet regimen Odefsey …
Janssen slams NICE decision on Imbruvica
March 2, 2016Research and Development, Sales and Marketing CLL, Cancer, Cancer Drugs Fund, Janssen, Johnson & Johnson, NICE, imbruvica
Janssen, the R&D arm of pharma major Johnson & Johnson, says it is extremely disappointed following regulator NICE’s announcement that …
Top 10 medicines issued in England by prescription cost in 2014-15
March 2, 2016Research and Development, Sales and Marketing Cost, Humira, NHS, prescription
AbbVie, Humira (adalimumab), £371m. This drug treats a variety of conditions including psoriatic arthritics, Crohn’s disease and ulcerative colitis. The …
Clinton steps up attacks on Valeant in latest campaign advert
March 2, 2016Research and Development, Sales and Marketing Hilary Clinton, Valeant
This is not the first time the pharma industry has drawn the ire of the US presidential hopefuls, but Hilary …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
